

ALVENTA PHARMA LIMITED

VILL. KISHANPURA, TEHSIL BADDI- NALAGARH ROAD, DISTT.- SOLAN (H.P) 174101

Quality Control Department

CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

Product Name	Clindacan 600	TROBE		
Generic Name		A.R. No.	FG/G/24A0046	
	Clindamycin Injection IP 150 mg/ml	Sample Quantity	65Ampoules	
Batch No.:	AA40509	Sample Received on		
Batch Size:	25500 Amp.		06/06/2024	
Mfg. Date.	05/2024	Analysis Date	06/06/2024	
Exp. Date		Release Date	20/06/2024	
Dap. Date	04/2027	Page No.:	Page 1 of 1	

Sr. No.	Test Parameter	A	cceptance Criteria		D :		
1. Description		1 1 .1 1 4		1 1 1	Result ml clear colourless liquid filled:		
		ml clear gla	ass ampoule with blue dot.		r colourless liqu	uid filled i	
2.	Identification:	o Trans with blue dot.			ml clear glass ampoule with blue dot		
	a) By HPLC	chromatogra					
	b) By TLC	obtained v	al spot in the chromatogram with the test solution to that in the chromatogram h the reference solution (a).	Complies			
3.	pH	Between 5.5	to 7.0	6.63			
4.	Extractable volume	Not less than	4.0 mI	4.05 ml			
5.	Particulate Matter	The Solution should be clear, colourless and free from any visible particle.		The Solution is clear, colourless and			
6.	Sterility	Should be sterile		free from any visible particle. Sterile			
	Bacterial Endotoxins Tests	Not more than 6.0 EU/ml of Less than 6.0 EU/ml of Clindamycin					
8.	Assay:						
	Each ml contains: Claim		Limit				
	Clindamycin Phosphate IP Eq. to Clindamycin Benzyl Alcohol (As Preservative) 150 mg 0.9%w/v		Between 90.0 % to 120.0 % of stated amount of Clindamycin (Between 135.0 mg to 180.0 mg)		mg 148.25 mg	98.83%	
					0.9121%w/v	101.34%	

Remarks: The above test parameters are complies/ not complies as per IP/BP/USP & In-House Specification.

Approved By
MOTE (0)
(Nautgon singh
Head- & A
4
2